137 related articles for article (PubMed ID: 3487056)
1. Parkinson-like syndrome in nonhuman primates receiving a tetrahydropyridine derivative.
Barsoum NJ; Gough AW; Sturgess JM; de la Iglesia FA
Neurotoxicology; 1986; 7(1):119-26. PubMed ID: 3487056
[TBL] [Abstract][Full Text] [Related]
2. [The effect of amiridin on the MPTP-induced Parkinson-like syndrome in monkeys].
Burov IuV; Metkalova SE; Kustov AE; Petrov GV; Shul'govskiĭ VV
Biull Eksp Biol Med; 1992 Nov; 114(11):495-7, 494. PubMed ID: 1290822
[TBL] [Abstract][Full Text] [Related]
3. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
[TBL] [Abstract][Full Text] [Related]
4. Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism.
Kito S; Miyoshi R; Mizuno K; Nitta K; Matsubayashi H; Yamamura Y; Tahara E
Adv Neurol; 1987; 45():159-65. PubMed ID: 2881441
[No Abstract] [Full Text] [Related]
5. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Goulet M; Madras BK
J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
[TBL] [Abstract][Full Text] [Related]
6. [MPTP and Parkinson's disease].
Imai H
No To Shinkei; 1988 Nov; 40(11):1011-24. PubMed ID: 3064783
[No Abstract] [Full Text] [Related]
7. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
Miyoshi R; Kito S; Ishida H; Katayama S
Res Commun Chem Pathol Pharmacol; 1988 Oct; 62(1):93-102. PubMed ID: 2849789
[TBL] [Abstract][Full Text] [Related]
8. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
Forno LS; Langston JW; DeLanney LE; Irwin I; Ricaurte GA
Ann Neurol; 1986 Oct; 20(4):449-55. PubMed ID: 3024555
[TBL] [Abstract][Full Text] [Related]
9. Study on MPTP-induced parkinsonian animal model in rhesus monkey and the mechanism of MPTP.
Chen SD; Xu DL; Yu HZ; Tang QM; Xu XR; Wang ZG; Liang PF
Chin Med J (Engl); 1988 Dec; 101(12):879-83. PubMed ID: 3150735
[No Abstract] [Full Text] [Related]
10. Hemiparkinsonism in monkeys following unilateral common carotid artery infusion of MPTP. A study of behavior, biochemistry and histology.
Chen SD; Zhou XD; Xu DL; Li GW; Tang QM; Xu XR
Chin Med J (Engl); 1991 Sep; 104(9):758-63. PubMed ID: 1935358
[TBL] [Abstract][Full Text] [Related]
11. MPTP: a pharmacological tool to study parkinsonism.
Kulkarni SK; Mehta AK; Aley KO; Shukla VK
Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
[TBL] [Abstract][Full Text] [Related]
12. [Intrathecal infusion of brain-derived neurotrophic factor protects nigral dopaminergic neurons from degenerative changes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced monkey parkinsonian model].
Takeda M
Hokkaido Igaku Zasshi; 1995 Nov; 70(6):829-38. PubMed ID: 8582706
[TBL] [Abstract][Full Text] [Related]
13. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D
Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625
[No Abstract] [Full Text] [Related]
14. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
15. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey.
Chiueh CC; Markey SP; Burns RS; Johannessen JN; Jacobowitz DM; Kopin IJ
Psychopharmacol Bull; 1984; 20(3):548-53. PubMed ID: 6332333
[No Abstract] [Full Text] [Related]
16. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
17. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
18. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
[TBL] [Abstract][Full Text] [Related]
19. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism.
Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
J Neural Transm Suppl; 1986; 20():41-6. PubMed ID: 3462325
[TBL] [Abstract][Full Text] [Related]
20. Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys.
Chiueh CC; Burns RS; Markey SP; Jacobowitz DM; Kopin IJ
Life Sci; 1985 Jan; 36(3):213-8. PubMed ID: 3871241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
